JHVEPhoto/iStock Editorial via Getty Images Bristol-Myers Squibb (NYSE:BMY) shares traded in the green on Friday, making it the seventh consecutive day of gains. The stock closed up 0.67% at $53.96. BMY stock fell about 5% in the last 12 months. YTD, the stock is trading up 5.6%, compared to the broader S&P 500 market which is up 19.50%. Looking at Seeking Alpha's Quant Ratings, this company has a Hold rating with a score of 3.47 out of 5. When it comes to Wall Street analysis, 17 out of 25 analysts recommend a Hold, 2 recommend a Strong Buy, 4 recommend it as a Buy, 1 recommends a Sell and 1 recommends a Strong Sell. According to SA analyst Zvi Bar, “Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. BMY's strong oncology portfolio, including Opdivo and Revlimid, and recent acquisitions bolster its fundamentals, targeting a price range of $59.50 to $61.60. Risks include revenue impact from Medicare's recent price negotiation for Eliquis and elevated debt from recent acquisitions.” Seeking Alpha analysts have a Buy rating on the company.